#BEGIN_DRUGCARD DB06681

# AHFS_Codes:
92:44

# ATC_Codes:
L04AA28

# Absorption:
Following multiple intravenous doses of an initial 10 mg/kg dose and followed by a maintenance dose of 5 mg/kg in kidney transplant recipients, these are the following pharmacokinetic parameters:
Cmax, 10 mg/kg = 247 µg/mL; 
Cmax, 5 mg/kg = 139 µg/mL;
AUC, 10 mg/kg = 22,252 µg · h/mL; 
AUC, 5 mg/kg = 14,090  µg · h/mL; 
Belatacept had linear and dose-dependent pharmacokinetic profile.

# Biotransformation:
The cytochrome P450 enzyme system or uridine diphosphate-glucuronosyltransferases are not expected to be involved with the metabolism of belatacept. Because the drug is a protein, belatacept is degraded into smaller peptides and amino acids by proteolytic enzymes.

# Brand_Mixtures:
Not Available

# Brand_Names:
Nulojix

# CAS_Registry_Number:
706808-37-9

# ChEBI_ID:
Not Available

# Chemical_Formula:
C3508H5440N922O1096S32

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
> sequence for belatacept MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTF
LDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPC
PDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED
PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

# Creation_Date:
2008-03-19 10:48:32 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Belatacept is a recombinant fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial for T-cell costimulation. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. It differs from abatacept (Orencia) by only 2 amino acids. FDA approved on June 15, 2011.

# Dosage_Forms:
Injection, powder, lyophilized, for solution	Intravenous

# Drug_Category:
Immunosuppressive Agents

# Drug_Interactions:
Belimumab 	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
Mycophenolate mofetil	Belatacept increases the Cmax and AUC of mycophenolate mofetil.
Pralatrexate	Increased immunosuppresive effects and risk of infection. Monitor for adverse effects .
Rilonacept	Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both.
Rilonacept	Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both.
Rilonacept	Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both.

# Drug_Reference:
22151353	Wekerle T, Grinyo JM: Belatacept: from rational design to clinical application. Transpl Int. 2012 Feb;25(2):139-50. doi: 10.1111/j.1432-2277.2011.01386.x. Epub 2011 Dec 7.
22928660	Garnock-Jones KP: Belatacept: in adult kidney transplant recipients. BioDrugs. 2012 Dec 1;26(6):413-24. doi: 10.2165/11208900-000000000-00000.
22928660	Garnock-Jones KP: Belatacept: in adult kidney transplant recipients. BioDrugs. 2012 Dec 1;26(6):413-24. doi: 10.2165/11208900-000000000-00000.

# Drug_Type:
Approved
Biotech

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Belatacept

# HET_ID:
Not Available

# Half_Life:
Mean terminal elimination half-life:
10 mg/kg, kidney transplant recipients= 9.8 days; 
5 mg/kg, kidney transplant recipient = 8.2 days

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D03222

# LIMS_Drug_ID:
6682

# Mechanism_Of_Action:
Belatacept is a fusion protein in which the Fc portion of human IgG1 is attached onto the extracellular portion of human CTLA-4 (CD152). Belatacept specifically binds to CD80 and CD86 receptors that are found on the antigen-presenting cell (B cells, macrophages, dendritic cells) to block selective T-cell lymphocyte costimulation. CD80 and CD86 would normally act as the ligands to the CD28 receptor T-cells in which this interaction triggers the activation of T lymphocytes. However in the presence of belatacept, because the extracellular CTLA-4 component binds to CD28 with higher affinity than CD80 or CD86, T lymphyocyte anergy, a state of antigen specific tolerance, occurs instead. The T cell is also no longer able to respond to their antigen.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
90 kDa

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Belatacept binds to CD86 with a 4-fold higher affinity than abatacept. It also binds to CD80 with a 2-fold higher affinity than abatacept. It was observed in non-human primates that belatacept prolongs graft survival due to a decrease in antibody production against the donor organ. Furthermore, belatacept also inhibits the primary humoral immune response which is indicated by the decrease in post-transplant levels of IgG, IgM, and IgA. The magnitude of this effect is more significant in belatacept than it is in cyclosporine.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB06681

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/nulojix-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
solid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
BMS-224818
LEA29Y

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-05-19 23:52:37 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Belatacept

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
18269922	Vincenti F: Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol. 2008 Feb;121(2):299-306; quiz 307-8.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CD86

# Drug_Target_1_GenBank_ID_Gene:
L25259

# Drug_Target_1_GenBank_ID_Protein:
439839

# Drug_Target_1_GeneCard_ID:
CD86

# Drug_Target_1_Gene_Name:
CD86

# Drug_Target_1_Gene_Sequence:
>972 bp
ATGGGACTGAGTAACATTCTCTTTGTGATGGCCTTCCTGCTCTCTGGTGCTGCTCCTCTG
AAGATTCAAGCTTATTTCAATGAGACTGCAGACCTGCCATGCCAATTTGCAAACTCTCAA
AACCAAAGCCTGAGTGAGCTAGTAGTATTTTGGCAGGACCAGGAAAACTTGGTTCTGAAT
GAGGTATACTTAGGCAAAGAGAAATTTGACAGTGTTCATTCCAAGTATATGGGCCGCACA
AGTTTTGATTCGGACAGTTGGACCCTGAGACTTCACAATCTTCAGATCAAGGACAAGGGC
TTGTATCAATGTATCATCCATCACAAAAAGCCCACAGGAATGATTCGCATCCACCAGATG
AATTCTGAACTGTCAGTGCTTGCTAACTTCAGTCAACCTGAAATAGTACCAATTTCTAAT
ATAACAGAAAATGTGTACATAAATTTGACCTGCTCATCTATACACGGTTACCCAGAACCT
AAGAAGATGAGTGTTTTGCTAAGAACCAAGAATTCAACTATCGAGTATGATGGTATTATG
CAGAAATCTCAAGATAATGTCACAGAACTGTACGACGTTTCCATCAGCTTGTCTGTTTCA
TTCCCTGATGTTACGAGCAATATGACCATCTTCTGTATTCTGGAAACTGACAAGACGCGG
CTTTTATCTTCACCTTTCTCTATAGAGCTTGAGGACCCTCAGCCTCCCCCAGACCACATT
CCTTGGATTACAGCTGTACTTCCAACAGTTATTATATGTGTGATGGTTTTCTGTCTAATT
CTATGGAAATGGAAGAAGAAGAAGCGGCCTCGCAACTCTTATAAATGTGGAACCAACACA
ATGGAGAGGGAAGAGAGTGAACAGACCAAGAAAAGAGAAAAAATCCATATACCTGAAAGA
TCTGATGAAGCCCAGCGTGTTTTTAAAAGTTCGAAGACATCTTCATGCGACAAAAGTGAT
ACATGTTTTTAA

# Drug_Target_1_General_Function:
Involved in coreceptor activity

# Drug_Target_1_General_References:
11162656	Magistrelli G, Caron G, Gauchat JF, Jeannin P, Bonnefoy JY, Delneste Y: Identification of an alternatively spliced variant of human CD86 mRNA. Biochem Biophys Res Commun. 2001 Feb 9;280(5):1211-5.
7520767	Engel P, Gribben JG, Freeman GJ, Zhou LJ, Nozawa Y, Abe M, Nadler LM, Wakasa H, Tedder TF: The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. Blood. 1994 Sep 1;84(5):1402-7.
7527824	Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, Ito D, Azuma M: CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol. 1995 Jan 1;154(1):97-105.
7541777	Jellis CL, Wang SS, Rennert P, Borriello F, Sharpe AH, Green NR, Gray GS: Genomic organization of the gene coding for the costimulatory human B-lymphocyte antigen B7-2 (CD86). Immunogenetics. 1995;42(2):85-9.
7694153	Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C: B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993 Nov 4;366(6450):76-9.
7694363	Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA Jr, Lombard LA, Gray GS, Nadler LM: Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993 Nov 5;262(5135):909-11.

# Drug_Target_1_HGNC_ID:
HGNC:1705

# Drug_Target_1_HPRD_ID:
03011

# Drug_Target_1_ID:
942

# Drug_Target_1_Locus:
3q21

# Drug_Target_1_Molecular_Weight:
37697

# Drug_Target_1_Name:
T-lymphocyte activation antigen CD86

# Drug_Target_1_Number_of_Residues:
329

# Drug_Target_1_PDB_ID:
1NCN

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF07686	V-set

# Drug_Target_1_Protein_Sequence:
>T-lymphocyte activation antigen CD86 precursor
MDPQCTMGLSNILFVMAFLLSGAAPLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQ
ENLVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGM
IRIHQMNSELSVLANFSQPEIVPISNITENVYINLTCSSIHGYPEPKKMSVLLRTKNSTI
EYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFSIELEDPQ
PPPDHIPWITAVLPTVIICVMVFCLILWKWKKKKRPRNSYKCGTNTMEREESEQTKKREK
IHIPERSDEAQRVFKSSKTSSCDKSDTCF

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-23

# Drug_Target_1_Specific_Function:
Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin 2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T- cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation

# Drug_Target_1_SwissProt_ID:
P42081

# Drug_Target_1_SwissProt_Name:
CD86_HUMAN

# Drug_Target_1_Synonyms:
Activation B7-2 antigen
B70
BU63
CTLA-4 counter-receptor B7.2
FUN-1
T-lymphocyte activation antigen CD86 precursor

# Drug_Target_1_Theoretical_pI:
6.91

# Drug_Target_1_Transmembrane_Regions:
248-268

# Drug_Target_2_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
16978033	Tedesco Silva H Jr, Pinheiro Machado P, Rosso Felipe C, Medina Pestana JO: Immunotherapy for De Novo renal transplantation: what's in the pipeline? Drugs. 2006;66(13):1665-84.
17616278	Yabu JM, Vincenti F: Novel immunosuppression: small molecules and biologics. Semin Nephrol. 2007 Jul;27(4):479-86.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
CD80

# Drug_Target_2_GenBank_ID_Gene:
M27533

# Drug_Target_2_GenBank_ID_Protein:
306916

# Drug_Target_2_GeneCard_ID:
CD80

# Drug_Target_2_Gene_Name:
CD80

# Drug_Target_2_Gene_Sequence:
>867 bp
ATGGGCCACACACGGAGGCAGGGAACATCACCATCCAAGTGTCCATACCTCAATTTCTTT
CAGCTCTTGGTGCTGGCTGGTCTTTCTCACTTCTGTTCAGGTGTTATCCACGTGACCAAG
GAAGTGAAAGAAGTGGCAACGCTGTCCTGTGGTCACAATGTTTCTGTTGAAGAGCTGGCA
CAAACTCGCATCTACTGGCAAAAGGAGAAGAAAATGGTGCTGACTATGATGTCTGGGGAC
ATGAATATATGGCCCGAGTACAAGAACCGGACCATCTTTGATATCACTAATAACCTCTCC
ATTGTGATCCTGGCTCTGCGCCCATCTGACGAGGGCACATACGAGTGTGTTGTTCTGAAG
TATGAAAAAGACGCTTTCAAGCGGGAACACCTGGCTGAAGTGACGTTATCAGTCAAAGCT
GACTTCCCTACACCTAGTATATCTGACTTTGAAATTCCAACTTCTAATATTAGAAGGATA
ATTTGCTCAACCTCTGGAGGTTTTCCAGAGCCTCACCTCTCCTGGTTGGAAAATGGAGAA
GAATTAAATGCCATCAACACAACAGTTTCCCAAGATCCTGAAACTGAGCTCTATGCTGTT
AGCAGCAAACTGGATTTCAATATGACAACCAACCACAGCTTCATGTGTCTCATCAAGTAT
GGACATTTAAGAGTGAATCAGACCTTCAACTGGAATACAACCAAGCAAGAGCATTTTCCT
GATAACCTGCTCCCATCCTGGGCCATTACCTTAATCTCAGTAAATGGAATTTTTGTGATA
TGCTGCCTGACCTACTGCTTTGCCCCAAGATGCAGAGAGAGAAGGAGGAATGAGAGATTG
AGAAGGGAAAGTGTACGCCCTGTATAA

# Drug_Target_2_General_Function:
Involved in coreceptor activity

# Drug_Target_2_General_References:
10661405	Ikemizu S, Gilbert RJ, Fennelly JA, Collins AV, Harlos K, Jones EY, Stuart DI, Davis SJ: Structure and dimerization of a soluble form of B7-1. Immunity. 2000 Jan;12(1):51-60.
1377173	Selvakumar A, Mohanraj BK, Eddy RL, Shows TB, White PC, Dupont B: Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7. Immunogenetics. 1992;36(3):175-81.
1714935	Freeman GJ, Gray GS, Gimmi CD, Lombard DB, Zhou LJ, White M, Fingeroth JD, Gribben JG, Nadler LM: Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med. 1991 Sep 1;174(3):625-31.
2794510	Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM: B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1989 Oct 15;143(8):2714-22.
7527824	Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, Ito D, Azuma M: CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol. 1995 Jan 1;154(1):97-105.

# Drug_Target_2_HGNC_ID:
HGNC:1700

# Drug_Target_2_HPRD_ID:
00202

# Drug_Target_2_ID:
944

# Drug_Target_2_Locus:
3q13.3-q21

# Drug_Target_2_Molecular_Weight:
33048

# Drug_Target_2_Name:
T-lymphocyte activation antigen CD80

# Drug_Target_2_Number_of_Residues:
288

# Drug_Target_2_PDB_ID:
1I8L

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF07686	V-set
PF08205	C2-set_2

# Drug_Target_2_Protein_Sequence:
>T-lymphocyte activation antigen CD80 precursor
MGHTRRQGTSPSKCPYLNFFQLLVLAGLSHFCSGVIHVTKEVKEVATLSCGHNVSVEELA
QTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLK
YEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGE
ELNAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFP
DNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-34

# Drug_Target_2_Specific_Function:
Involved in the costimulatory signal essential for T- lymphocyte activation. T-cell proliferation and cytokine production is induced by the binding of CD28 or CTLA-4 to this receptor

# Drug_Target_2_SwissProt_ID:
P33681

# Drug_Target_2_SwissProt_Name:
CD80_HUMAN

# Drug_Target_2_Synonyms:
Activation B7-1 antigen
B7
BB1
CTLA-4 counter-receptor B7.1
T-lymphocyte activation antigen CD80 precursor

# Drug_Target_2_Theoretical_pI:
7.71

# Drug_Target_2_Transmembrane_Regions:
243-263

#END_DRUGCARD DB06681
